The 2021 Annual
PRIMO Meeting Agenda
- Practical considerations of applying biomarkers and targeted therapy
- Integration of immunotherapy, with a focus on novel management approaches
- Patient selection, as well as timing and sequencing of therapy
- Dealing with important trends, such as big data and defining value in cancer care
NOTE: All times listed are in Central Standard Time (CST)
09/01/2020 - 10/31/2020
11/01/2020 - 12/31/2020
01/01/2021 - 02/10/2021
Registration is FREE for all Healthcare Practitioners
Join your colleagues and explore key developments in cancer care over the past 12 months as well as the anticipated advances that you and your patients will likely see in the upcoming year.
This activity has been designed to meet the educational needs of Academic and Community Practitioners, as well as Registered Nurses and Advanced Practice Registered Nurses, Pharmacists and Physician Assistants from all oncology specialties, treating all disease sites involved in the care of patients with cancer.
After completing this activity, the participant should be better able to:
- Describe the rationale for mechanisms of action for molecular targeted and immunologic therapies used to treat cancer today;
- Summarize recent advances in targeted and immunologic treatment of hematologic malignancies and solid tumors;
- Identify patients who are appropriate candidates for targeted and immunologic therapies;
- Implement strategies from a healthcare team approach to reduce treatment-related toxicities, and optimize patient outcomes;
- Discuss promising targeted and immunologic approaches being tested in late-stage clinical trials.
at a Glance
THE PRACTICAL RECOMMENDATIONS IN IMMUNO AND MOLECULAR ONCOLOGY MEETING is a unique opportunity to receive CME/CE credits while staying ahead of the latest advances in immuno and molecular oncology.
The Annual PRIMO Meeting is designed to summarize key developments in cancer care over the past 12 months and features anticipated advances that you and your patients will likely see in the upcoming year.
Accreditation and Credit Statements
In support of improving patient care, the Medical Educator Consortium is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 10.25 Interprofessional Continuing Education (IPCE) credit for learning and change.
The Medical Educator Consortium designates this live activity for a maximum of 10.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Medical Educator Consortium designates this activity for 10.25 contact hours. Pharmacotherapy contact hours for Advance Practice Registered Nurses will be designated on your certificate.
This Application-based activity has been approved for 10.25 contact hours (1 CEU) by the Medical Educator Consortium. The Universal Activity Number for this program is JA4008179-0000-21-002-L01-P Your CE credits will be electronically submitted to CPE Monitor® within 60 days upon successful completion of the activity.
The Medical Educator Consortium (MEC) adheres to the Joint Accreditation Criteria and ACCME Standards for Commercial Support, which requires everyone in a position of controlling the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests related to the activity content. MEC has implemented a mechanism to identify and resolve all conflicts of interest prior to the CME/CE activity being delivered to learners. The source of all support from commercial interests will also be disclosed to learners prior to the beginning of the educational activity. CME/CE activities must be balanced, independent of commercial bias, and designed to improve quality in health care. All recommendations involving clinical medicine must be based on evidence within the medical profession.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contradictions, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contradictions and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.